Life Science Success (Don Davis PhD, MBA)

Michael Papadimitrious is the Medical Affairs Manager for Miltenyi Biomedicine.  In this episode, Michael and I have a fantastic conversation about CAR-T therapy, delivering personalized cancer therapy and what the future may hold as science continues to evolve. 

In this episode of the Life Science Success podcast, my guest is Dr. Scott Wagers.  Scott is the CEO of BioSci Consulting, the author of Assembled Chaos, and the host of Beyond Publications podcast. (Consortium Whisperer)

• Dr. Scott Wagers helps people develop consortium projects to speed up the realization of the future of medicine.
• The translational gap is the delay between research findings and clinical implementation, and it takes about 17 years to cross.
• The bottleneck in the translational gap is the resistance to change and the lack of adoption.
• AI has the potential to free humans to focus on what they're really optimized for, which is creativity, pattern recognition, and working together.
• The human mind is optimized for certain things that AI can free us to focus on.
• Collective thinking of a bunch of different people is a very powerful computer in its own right.
• Leadership isn't just at the very top level; it's at every level, down to the PhD student who writes an outline or an SOP.
• Beyond Publications is a podcast about going beyond publications and pushing through the translational gap.
• Patients inspire Dr. Scott Wagers, and the translational gap concerns him.
• The dynamic of collective thinking and working together excites Dr. Scott Wagers.

In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US.

The key highlights from the interview:

• Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject.

• His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment.

• Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue.

• Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively.

• His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging.

• Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes.

• He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event.

• The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.

We discuss everything from SEO to current and future challenges in patient recruitment.  

In this episode of Life Science Success, my guest is Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience in the biotech and pharma industries, Ravi is a seasoned Biochemical Engineer who has worn many hats throughout his career. Prior to his current role, he served as the President of Azzur Cleanrooms on Demand™ and was also the General Manager of Azzur Boston. He's an expert in areas such as phase-appropriate cGMP implementation, process validation, and supplier management.

• Ravi Samavedam is the Chief Innovation Officer at Azzur Group, with over two decades of experience in the biotech and pharma industries. He transitioned from a biochemical engineer to his current role, having worked at companies like Baxter, Shire, and Amgen.

• His role at Azzur Group involves exploring potential growth areas for the company, such as their "Clean Rooms on Demand" business. This service aims to provide a flexible, cost-effective solution for companies in the biopharma sector, bridging the gap between traditional manufacturing options.

• Samavedam emphasizes the importance of innovation and impact in the healthcare industry. He believes that smaller, agile companies like Azzur can make a more significant impact compared to larger organizations where individual contributions may get diluted.

• One of the challenges he faces is educating the industry about new, more efficient models of operation. Traditional methods are often deeply ingrained, making it difficult for companies to see the value in innovative solutions like Azzur's.

• His leadership philosophy is "Don't let perfect get in the way of good," emphasizing the importance of practicality and risk mitigation in the pursuit of excellence. He is excited about the future of personalized medicine and believes that technology will continue to reduce inherent risks in biopharma processes.

In this episode, I interviewed Mark Charbonneau. Mark is a biotechnology R&D leader with cross-functional expertise in live biotherapeutic drug development, mechanistic modeling, computational biology, and biomarker assay development. He integrates technical acumen and emotional intelligence to build high-functioning teams and foster innovation.

This week on Life Science Success, I interviewed Chris Yeh. Chris is the Co-Author of Blitzscaling. We will be talking about blitzscaling, key factors to blitzscale, and key things Chris looks for when working with companies.

In this episode of Life Science Success, my guest is Nusqe Spanton.  Nusqe is the founder and CEO of Provectus Algae. He is an aquaculture and algae expert with nearly two decades of experience working in international aquacultural production, marine biotechnology, and corporate management.

• Nusqe Spanton discusses the potential of marine microorganisms to produce commercially valuable compounds.
• The company, Provectus, is focused on developing products for food, agriculture, and cosmetics, as well as oral fertility treatments.
• The company is still in an early phase of development and has around 30 employees.
• Spanton emphasizes the importance of making quick and decisive decisions as a leader, especially in a startup environment.
• He also stresses the need to move quickly in addressing environmental concerns.
• Spanton is inspired by his children and the potential of the younger generation to effect change.
• He is excited about building a great business with like-minded individuals and being a problem solver.

This week on the Life Science Success podcast my guest is Jenifer Wheat. Jenifer has a unique combination of skills in scientific, regulatory, legal, and business development expertise. She has extensive knowledge of biopharmaceutical manufacturing and business life cycles. Given her background and career, she has negotiated agreements internationally in the US, EU, Korea, Japan, Canada, Australia and the Middle East.

Matt Hicks CEO of Federal Equipment Company 

In this episode, we discuss Matt's career and how his equipment company acquires and sells pharma equipment.  Matt recently published an article titled "Reshoring a Nation’s API and Pharmaceutical Production"

In this episode of Life Science Success my guest is Alex Chen.  Alex is the President of Overseas Operations at uBriGene Biosciences Inc.

• He has diversified experience, having worked in various industries such as mining, real estate, and investment banking before joining uBriGene Biosciences Inc.
• uBriGene Biosciences Inc. is a biotech company that provides services ranging from upstream to downstream, including QC testing
• The company is focused on innovation and utilizes the most up-to-date technologies to provide cost-effective and quality products
• uBriGene Biosciences Inc. has sites in the US and China, and its core competency is research and development
• The company aims to be a partner with its clients and grow with them
• uBriGene Biosciences Inc. has over 500 employees globally and has raised $100 million to date

In this episode of the Life Science Success Podcast my guest is Patrick Moran, an attorney and entrepreneur who transitioned from industrial agriculture and healthcare to life sciences with his groundbreaking work at Pebble Life Science. Patrick's innovative research, which began with a prototype showing promising results for children with autism, has led to the development of a unique intellectual property and patent strategy that could potentially transform therapeutic approaches in neurodevelopmental conditions.

00:00 Introduction to the Podcast
00:28 Meet Patrick Moran: From Agriculture to Life Sciences
00:55 Patrick's Journey and Early Career
05:15 Transition to Life Sciences and Early Prototypes
07:52 Lessons Learned and Career Milestones
16:04 Pebble's Mission and Impact on Autism
17:05 Current Growth and Future Directions
25:21 Challenges and Overcoming Obstacles
27:33 Personal Insights and Leadership Advice
35:03 Conclusion and Final Thoughts

This week we are taking a brief break from interviewing guests and I am talking about recent changes in the Life Science Success website (www.lifesciencesuccess.com) and an upcoming event with Music Beats Cancer.

In this episode of the Life Science Success Podcast, my guest is Dr. Zachary S. Brooks, a serial entrepreneur, #1 Best Selling Author, and founder of UGenome AI. Dr. Brooks brings a wealth of experience from his diverse background in technology startups, financial services, and digital authentication. As the founder of UGenome AI, he's at the forefront of developing innovative SaaS tools for genomic medicine. We'll explore his journey from studying bilingual decision-making to becoming a leader in the life sciences field, and discuss how his experiences as an international athlete and multilingual individual have shaped his approach to business and innovation. Dr. Brooks will share insights on the future of personalized medicine, the intersection of genomics and organ transplantation, and the challenges of bringing cutting-edge technology to market. We'll also delve into his work with World Transplant Athletes and his vision for improving healthcare outcomes for organ transplant recipients. This episode promises to be an inspiring and informative conversation about the exciting developments in genomic medicine and the power of entrepreneurship in the life sciences.

In this episode of Life Science Success, my guest is John Houston, Ph.D., the Chairperson, Chief Executive Officer, and President of Arvinas. With over three decades of experience in drug discovery and development, Dr. Houston brings valuable insights into pioneering protein degradation therapeutics and the challenges of leading a cutting-edge biotech company.

In this episode of the Life Science Success podcast I interviewed Ramani Varanasi.  Ramani is a Biopharma Executive, Board Member, CEO, Founder/Entrepreneur, Advocate & Optimist.  In this episode, we  discussed her career, where she serves as a trusted partner to CEOs and Executive Management and advises on corporate strategy, fundraising, corporate development, and operations. 

In this episode of the Life Science Success podcast my guest is Raj Indupuri.  Raj is the CEO of eClinical Solutions.  He is also a technologist with significant industry experience, passionate about fostering innovation to revolutionize the Life Sciences industry with ground-breaking technologies that will modernize clinical trials and bring treatments to patients faster.

In this episode of Life Science Success, we're thrilled to welcome Britney Winterberger, the Senior Director of North America Project Management and Clinical Operations at Tigermed. Britney brings a wealth of experience in clinical trials across various therapeutic areas and a deep personal commitment to advancing patient treatments, particularly in the fight against cancer.

• Britney Winterberger is the Senior Director of North America Project Management and Clinical Operations at Tigermed, with a rich career history in life sciences, inspired by a personal loss to leukemia. She initially aspired to be a pediatric oncologist but shifted towards clinical research to contribute to cancer treatment advancements.
• Winterberger, who was born and raised in Cincinnati, Ohio, has a Marquette University undergraduate degree in biological sciences as well as study abroad experiences. She is also a family person, emphasizing the importance of travel, outdoor activities, and being sports enthusiasts with her husband and two children.
• Her journey into the field of life sciences was somewhat unintentional, transitioning from a goal in pediatric oncology to clinical research due to the emotional challenges of the former. She transitioned because of a special opportunity through a family connection, which led her to a career in clinical research organizations (CROs).
• Throughout her career, pivotal moments included receiving a 'B' on a performance review, which was a significant learning experience for her, highlighting the importance of adaptability, innovation, and the need to work in a more agile and innovative environment. Joining Tigermed represented a culminating point where she found a space to innovate and drive meaningful change in the clinical research landscape.
• Winterberger discusses the evolution of clinical trials, emphasizing the shift towards patient-centric approaches, the integration of digital health technologies, and the push for decentralized clinical trials to improve patient access and compliance. She also highlights Tigermed's role in advancing clinical research through innovative trial designs and efficient patient recruitment strategies, underlining her commitment to making a difference in cancer treatment and patient care.

In this episode of Life Science Success, we dive deep with Dr. John L. LaMattina, former president of Pfizer Global R&D and current biotech industry leader. From groundbreaking drug discoveries to shaping the future of pharmaceuticals, Dr. LaMattina shares his journey from the lab to the boardroom. Gain unique insights into innovation, challenges, and opportunities in life sciences as we explore the ever-evolving world of drug development. Whether you're an industry professional or simply curious about the future of healthcare, this conversation promises to inform and inspire.

This week on the Life Science Success Podcast my guest is Dan Lunz. Dan Lunz is the CEO and Co-founder of Previse, a pioneering company based in Baltimore, Maryland, that specializes in offering tests for the prediction and earlier detection of upper-GI cancers.

• Background of Dan Lunz: Dan Lunz, CEO and co-founder of Previse, shares his journey from growing up in Baltimore, serving in the Marine Corps, experiencing healthcare firsthand as a patient in the VA system, to studying at Johns Hopkins and working in clinical research. His career path was significantly influenced by his desire to serve others, leading him to the life sciences sector.

• Formation of Previse: Lunz's collaboration with Dr. Steven Meltzer, a professor at Johns Hopkins, sparked the founding of Previse. They focused on developing diagnostic tools for early detection of upper GI cancers based on Meltzer's research on biomarkers. Their shared mission was to improve patient outcomes through innovative medical technologies.

• Previse's Diagnostic Innovations: Previse specializes in detecting and predicting upper gastrointestinal (GI) cancers. The company offers a commercial test called ESO Predict, which assesses the risk of esophageal cancer in patients with conditions like Barrett's esophagus, helping physicians strategize patient management and surveillance intervals.

• Challenges and Leadership Insights: Throughout the interview, Lunz discusses the entrepreneurial challenges of securing funding and navigating regulatory landscapes. He emphasizes the importance of perseverance and humility in leadership, learning from rejections, and the critical role of assembling a talented team to overcome complex challenges.

• Future Goals and Impact: Looking forward, Previse aims to expand access to its existing diagnostics across the U.S. and continue developing non-endoscopic tools and medical devices to enhance GI cancer detection. Lunz is driven by the potential impact of their technology in preventing cancer and improving patient care, underscoring his dedication to service and innovation in life sciences.

This week's guest is Dave Bjork the Research Evangelist. He is a Patient Advocate, Lung Cancer Survivor, Speaker and Advisor. His career spans more than 20 years of progressive experience in nonprofit marketing, patient advocacy and fundraising leadership roles including Vice President of Development, National Foundation for Cancer Research, Bethesda, MD. In this role, He launched several fundraising and advocacy programs and became known as the “Cancer Research Evangelist” because of his dedication and commitment to basic scientific research. He also hosts the Research Evangelist Podcast.  

Jennifer Hawks Bland is a distinguished leader in the life sciences sector, serving as the Chief Executive Officer of NewYorkBIO, an organization at the forefront of advancing New York's life sciences ecosystem. With a rich background spanning legal practice, government affairs, and executive leadership in companies like Merck and GlaxoSmithKline, she brings a wealth of experience and insight to her role in fostering innovation and growth within the industry.

• Jennifer Hawks Bland, CEO of New York Bio, discussed her unique path into life sciences, transitioning from a legal background where she initially engaged with the pharmaceutical industry through mass tort defense litigation, to advocacy and lobbying roles, eventually leading her to her current position.
• She detailed the mission and operations of New York Bio, highlighting its role in advancing New York’s life sciences ecosystem by collaborating with early-stage companies, academic medical centers, and leveraging the state’s rich resources in life sciences for regional and statewide economic development.
• Hawks Bland emphasized the importance of storytelling in advocacy, drawing on her legal and lobbying background to influence policy and support the life sciences industry, both at the state and federal levels, and how this skill has been crucial in her roles leading up to and including her leadership at New York Bio.
• The conversation also covered the challenges and opportunities facing the life sciences sector, particularly in New York, from fostering startup growth to navigating policy and funding landscapes. She stressed the significance of collaboration across various stakeholders, including government, academia, and the private sector, to drive innovation and support the ecosystem.
• Hawks Bland shared her excitement for the future of life sciences, reflecting on the potential for breakthroughs in health and medicine, and the critical role of advocacy and strategic partnerships in overcoming challenges and capitalizing on opportunities within the industry.

This week on the Life Science Success Podcast my guest is Jae Yoo.  Jae is the Executive Director at EPM Scientific.  EPM Scientific exists to enable exceptional careers around the world. They connect exceptional talent, with exceptional opportunities.

In this episode of life science success my guest is Barb Pearlman.  Barb is the President Cambridge Scientific Products / CEO of Cambridge Scientific Labs, Watertown's First Biotech Incubator.

In this episode of the Life Science Success Podcast my guest is Vadim Klyushnichenko, Ph.D,   Vadim is the VP Pharmaceutical Development at Scripps Research.  He has over 25 years of progressive experience in Global Bio/Pharmaceutical Development from Discovery to Clinical and Commercial Manufacturing.

In this episode of Life Science Success, my guest is John McDonough, the Executive Chairman and CEO of Sunbird Bio. John is a seasoned life sciences executive with over 30 years of experience, known for his impressive track record of raising capital and creating substantial market value. He currently leads Sunbird Bio, a company at the forefront of developing innovative blood-based diagnostic tests for neurological disorders, particularly Alzheimer's disease. John's expertise extends beyond Sunbird Bio, as he also serves as chairman at Cytrellis Biosystems and BioPorto Diagnostics, and is the founder and president of the Crush Colon Cancer Foundation. With a history of successful IPOs, acquisitions, and mergers, John brings a wealth of knowledge and experience to our conversation about the future of neurological diagnostics and the life sciences industry.

This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.

On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them.

• Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients.
• Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications.
• One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs.
• Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine.
• His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.

In this Episode of the Life Science Success Podcast I am joined by Mark Collins PhD, Dusty Majumdar PhD and Janik Jaskkolski in a panel discussion about Artificial Intelligence. We cover the current state, eliminating mundane tasks in healthcare, what will happen before we see further adoption of AI and the future state of the field.

In this episode of Life Science Success, host Don Davis PhD, MBA interviews Yaky Yanay, the CEO of Pluri, an innovative Israeli biotech company. Dr. Davis explores Pluri's groundbreaking work in regenerative medicine using placenta-derived cells. Yanay explains their unique allogeneic approach, which allows for the use of cells from healthy donors to treat various conditions without the need for genetic matching.

This week on the Life Science Success Podcast my guest is Jitendra Pant.  He is an experienced Researcher with 13+ years of expertise in Clinical and Translational Research, Biocompatible Invasive Biomedical Devices, In vitro Biology, FDA approved Immunotherapeutic (Cancer and Autoimmune disorders), Bioprocess Development, Antibacterial, and Antithrombotic Biomaterials, Tissue Engineering applications, Macro and Microencapsulation technology for making artificial pancreas for Type 1 Diabetes (T1D) treatment.  He is also an entrepreneur and 2x TEDx Speaker.

In this episode of Life Science Succes, I interview  Christopher Pirie CoFounder and COO of HDT Bio. His technical experience is centered primarily on protein/enzyme engineering with forays into synthetic biology, metabolic engineering, polymers, drug delivery, and biopharmaceuticals.

In entrepreneurship Christopher is motivated by alternative financing/business models for commercialization of cutting-edge technologies, creative strategies for protection of intellectual property, and a laser-focus on customer engagement and end-user value creation.

This week on the podcast I interview Jacob Glanville, PhD we discuss Jacob's journey that led him to Distributed Bio then to Centivax and his work on the Netflix show Pandemic. Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.

In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs.  Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion.

• Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. 

• James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion.

• Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens.

• Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology.

• Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.

This week I am joined by Raymond Peterson the CEO of DNA Analytics and we will be discussing the use of AI in establishing DNA targets.  Therapy for viruses with honey bees.  

In this episode of the Life Science Success Podcast, we dive deep into the world of health communication with Michelle Bridenbaker, COO of Unbiased Science at Vital Statistics Consulting. Michelle shares her journey from nursing to leadership in health communications, offering insights into the challenges of conveying accurate scientific information in today's media-saturated landscape. She discusses innovative strategies for pharmaceutical companies to effectively reach healthcare professionals and combat misinformation. Michelle also explores the role of digital transformation in health communication and provides a glimpse into the future of scientific engagement. With her unique perspective on balancing regulatory compliance and dynamic audience engagement, this episode offers valuable insights for anyone interested in the intersection of healthcare, communication, and technology.

In this episode of the Life Science Success Podcast, Don Davis PhD, MBA interviews Igor Fisch, founder of NewBiologix. Igor shares his journey from academia to entrepreneurship, highlighting his success with Selexis, a company he sold in 2017 that specialized in monoclonal antibodies. He discusses the challenges of gene therapy, specifically the high costs, and NewBiologix's innovative approach to making gene therapy more affordable. Igor also provides insights into the industry's future, emphasizing the significance of stable production platforms for viral particles.

00:00 Introduction and Welcome

00:15 Igor's Journey into Life Sciences

00:37 The Success of Selexis

00:56 Transition to Gene Therapy

03:32 Challenges in Gene Therapy

03:50 The Importance of Stable Platforms

05:11 The Role of Biotech Startups

05:57 Balancing Science and Business

06:51 Networking at BIO Conference

08:14 Future Vision for New Biologics

09:21 Conclusion and Farewell

In this episode of Life Science Success, my guest is Mara Holinger.  Mara is the SVP and co-founder of Quantum Regulatory Solutions.  She has extensive experience in assisting pharmaceutical and biotech firms with preparing their regulatory pathway, providing regulatory input for clinical trial designs and clinical development plans, performing gap analyses for preclinical testing and writing regulatory applications.

Key points covered in this interview: 

1. Background and Expertise: Mara Holinger has a strong background in Regulatory Affairs, with a Ph.D. in a related field. She also highlighted her co-founders' scientific expertise, making their team unique in the regulatory consulting field.

2. Client Base: Quantum Regulatory Solutions primarily serves small to midsize pharmaceutical companies, offering a range of services beyond just regulatory strategy, including pre-meeting support and long-term pathway planning.

3. Team Collaboration: Mara emphasized the importance of collaboration within her team, combining their diverse skill sets to provide comprehensive solutions to clients. This collaborative approach sets them apart from others in the field.

4. Leadership and Empowerment: She mentioned the value of strong leadership and role models who encouraged her to speak up and not apologize for her opinions. This empowerment has been crucial in her career.

5. Passion for Problem-Solving: What excites Mara is the opportunity to solve complex puzzles in the regulatory space, working closely with various stakeholders to ensure that innovative therapies can navigate the regulatory process successfully.

My guest on the Life Science Success Podcast is Jeff Wessinger.  Jeff is the VP of Life Sciences for PointClickCare (PCC).  We are going to discuss how PCC is providing the de-identified data companies need to improve care outcomes and expand drug discovery and development.

Broderick Jones is a seasoned executive with 25 years of experience in Healthcare, Life Sciences, and Financial Services, known for driving growth and operational excellence across key business functions. Currently serving as a senior leader at Verista, he brings his expertise in compliance and validation services to the pharmaceutical, medical device, and biotechnology industries.

Today on the Life Science Success Podcast my guest is Katherine Lynch.  Katherine serves as a Senior Vice President within (TCC) Trammell Crow Company’s Atlanta Business Unit. She is responsible for sourcing, shaping and executing TCC’s office and life sciences development and investment in Atlanta, and the Southeast.

In this episode of Life Science Success, my guest is Meredith Manuel.  Ms. Manuel is a proven leader with drive and determination in the scientific industry, specializing in global drug development and project management.  

Key Takeaways:

• Introduction to Meredith Manuel: Meredith Manuel is an accomplished leader with extensive experience in the scientific industry, particularly in global drug development and project management.

• Focus on Life Sciences: The podcast features a conversation between Meredith Manuel and the host, Don, who is a consultant specializing in helping companies within the life sciences sector enhance their strategies, processes, and technologies.

• Exploring Spatial Biology: Meredith discusses her role at "enable" where she manages the commercial division of a company focused on spatial biology. Spatial biology involves analyzing markers and molecules in the context of tissue, allowing for a deeper understanding of cell interactions and disease mechanisms.

• Impact on Drug Development: The application of spatial biology in drug development is highlighted, emphasizing the importance of moving beyond traditional single biomarker approaches. Integrating various data sets and understanding complex interactions within tissues is seen as crucial for advancing drug development.

• Leadership and Collaboration: Meredith also shares insights about leadership and collaboration, encouraging individuals to advocate for themselves and promote diversity of perspectives. She emphasizes the need for open communication within teams and across disciplines, especially in the dynamic field of life sciences.

Details:

Meredith Manuel is introduced as a guest on the "Life Science Success Podcast." The podcast is hosted by Don, a life sciences consultant focusing on improving companies' strategies, processes, and technology within the life sciences sector. Meredith has a strong background in the scientific industry, with a focus on global drug development and project management. She has a lifelong fascination with science, dating back to kindergarten when she first became interested in the field. Her career has spanned different areas of drug development, and she is particularly passionate about spatial biology, a cutting-edge technology that involves analyzing markers and molecules in tissue context.

Meredith's role at "enable" involves managing the commercial division of a company that specializes in spatial biology. She explains that spatial biology allows researchers to analyze cell interactions and disease mechanisms by studying markers in the context of tissue. This technology enables a more comprehensive understanding of disease processes and has applications in challenging areas like oncology and immunology. Meredith emphasizes that this approach goes beyond the traditional single biomarker paradigm, enabling a deeper understanding of complex biological processes.

Meredith discusses leadership and collaboration, drawing from her extensive experience. She encourages individuals, especially women, to advocate for themselves and share their ideas openly. She shares a story about a female boss who advised her to be her own advocate and speak up. She believes that diverse perspectives are crucial for innovation and problem-solving. Meredith underscores the importance of listening, collaboration, and communication in achieving successful outcomes within teams.

The conversation concludes with discussions about the challenges and potential future directions of spatial biology and drug development. Meredith expresses her desire to contribute to improving the healthcare industry and patient outcomes through her work. She also highlights the need for a patient-centered approach and collaboration between academia, industry, and regulatory bodies to drive progress in the field.

In this episode of Life Science Success, my guest is David Baram.  David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020.

• Don Davis, PhD, MBA interviews David Baram, PhD, CEO of Emendo Biotherapeautics
• Mendo is focused on developing gene editing therapies for rare and prevalent diseases, including cardiovascular diseases.
• They discuss the challenges of managing a company with different interests at play, including investors and patients.
• They touch on the potential of AI and the need for regulation and control.
• David shares his motivation and excitement in achieving his goals and seeing his inventions materialize.

Today I interview Michael Fero the Founder and President of TeselaGen. Michael and the team at TeselaGen have created an AI enabled operating system that can help biopharma companies design their next drug.  TeselaGen uses methods from machine learning and synthetic biology to help Pharmaceutical companies build and optimize cancer fighting drugs and vaccines by letting experimental data drive the discovery process.

• AJ Melet is the CEO of a startup biotechnology company Ronawk Inc.
• Ronawk Inc’s technology involves growing cells in a tissue mimetic substrate called bio blocks.
• The cells grow in 3D and form their own micro tissues, which can be used to manufacture new therapies.
• Roanoke's technology has potential applications in tissue engineering and scaling the production of biological factors.
• The biggest challenges Roanoke is currently facing are building a new lab and getting people to understand the new technology.
• AJ Melet is inspired by people who serve others, concerned about our ability to connect in a digital world, and excited by people tackling big challenges.

In this episode of the Life Science Success podcast my guest is Jeremy Stackawitz.  Jeremy has over 25 years of healthcare industry experience and 15 years of diagnostics experience. Before joining Senzo as CEO, from 2009-2021 Mr. Stackawitz held roles of CCO, President, and CEO at Quotient (QTNT), helping lead the company from start-up to IPO. 

In this episode of Life Science Success, my guest is Darwin Shurig, founder and CEO of Shurig Solutions.  Darwin brings strategic value to medical device, life science, and pharma companies. Darwin is responsible for most, if not all, business processes, including project management, recruitment, sales, operations, quality, and regulatory affairs, to mention a few.

The Happy Engineer 🎧 Top Podcast Host || Helping Thousands of Engineering Leaders Reach the Next Level (without Suffering Burnout) || World's Best Lifestyle Engineer || CEO & Career Coach 

In this episode of Life Science Success, my guest is Zach White.   Zach is the host of the Happy Engineer Podcast, and he is also a career coach who is helping thousands of engineering leaders reach the next level without suffering burnout. 

• Zach White discusses the challenges that engineers face in their careers, including continually increasing demands and the need to balance leadership development with technical knowledge.
• He also discusses the importance of mindset and coaching to help engineers achieve their goals and find fulfillment in their work.
• Zach is inspired by seeing clients take courageous steps and achieve what they previously thought was impossible.
• He is concerned about the impact of financial systems and policies on the economy and the need for continual learning in the face of rapidly advancing technology.
• Zach is excited about travel and the opportunity to experience new places and cultures.
• The Happy Engineer Podcast, hosted by Zach, focuses on helping engineers build their careers, balance their lives, and find happiness along the way.

In this episode of the Life Science Success podcast, my guest is Bremer Louw.  Bremer is the vice president of operations at Bioforum, a data focused CRO. He has been in the clinical research industry for over 15 years and has extensive experience in data management and biostatistics programming.

Bremer Louw, VP of Operations at Bioform, discusses the company's focus on meeting customer needs and building solutions for complex problems. He also expresses concerns about the pace of innovation and the ethical and regulatory implications of machine learning and artificial intelligence in the life sciences industry. Louw emphasizes the importance of small successes and momentum in achieving larger goals.

• Bioform is a smaller, more nimble organization with a different culture than larger companies like IQVIA.
• Bioform is attentive to customers' needs and works to meet them on an individual basis.
• Bremer Louw, the VP of Operations at Bioform, is responsible for overseeing operational metrics, professional services, quality, business development, and innovation.
• Bioform works with both drug and diagnostic companies.
• Louw is concerned about the pace of innovation in the industry and the ethical and regulatory implications of machine learning and artificial intelligence.
• Louw emphasizes the importance of small successes and momentum in achieving larger goals.

In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch.

• The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint.
• Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain.
• ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself.
• The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach.
• Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.

To connect with the guest, links and show notes please visit: www.lifesciencesuccess.com

In this episode we talk to Dr. Andrews from BD about the team's work on the COVID task force, the test that has been developed for SARS COV-2 to provide rapid results to patients on the Veritor platform and lastly Dr. Andrews work in Womens Health and Cancer at Becton Dickinson.  

This week on the Life Science Success podcast I interviewed David Sanders.  David is an experienced Business and Advocacy Professional with a demonstrated history of success creating business and policy changes and improving outcomes in the technology, IP, pharmacy, pharmaceutical, & healthcare services industries.  We are going to be talking about David’s Government Affairs and Public Policy work & Securing America's drug supply in the US.

In this episode of the Life Science Success Podcast my guest is Pierre Morgon, a seasoned life science executive with over 35 years of experience in global pharmaceutical operations, startup leadership, and board governance. Pierre is the CEO of MRGN Advisors and brings extensive expertise across specialty care, vaccines, and immunotherapy, with a distinguished background that includes multiple leadership roles in multinational corporations and innovative biotech startups.

00:00 Introduction to the Podcast
00:42 Sponsor Message: Bio on the Bayou 2025
02:16 Guest Introduction: Pierre Morgon
02:47 Pierre's Career Journey and Key Milestones
06:35 Lessons from Big Pharma to Startups
09:44 Managing Multiple Roles and Time
11:51 Challenges and Objectives of Various Companies
17:55 Board Leadership in Life Sciences
23:25 The Future of Formal Education and AI
30:03 Advice for Aspiring Life Science Professionals
34:40 Innovative Projects and Leadership Insights
40:08 Conclusion and Final Thoughts

In this episode of Life Science Success my guest is Roger Frechette.  Roger is the co-founder and principal of New England PharmAssociates, LLC.  He leverages a global network and insights derived from his greater than 20 years experience in the Business of Biotech and R&D Operations, calibrated with a background as a scientist and scientific leader.

In this episode of Life Science Success my guests are Rahul Sharma, the co-founder and CSO of Scienetix, a company dedicated to enabling Molecular Diagnosis. Dr. Sharma is a board-certified laboratory director and technical lead for Next Generation Sequencing (NGS) and PCR-based assay development and clinical testing. He has developed multiple Molecular Diagnosis tests and translated them into clinical testing. 

Additionally, We are joined by Rob Carpenter PhD, MBA the CEO of Scienetix.  Rob is a healthcare executive and educator with over 25 years’ experience in developing, managing, and assimilating healthcare companies. He is distinctly skilled in business development and various business growth strategies. He is founder and current CEO of Advanta Genetics, a highly complex clinical and research laboratory accredited by the College of American Pathologists with concentration in infectious disease molecular genomics and Scienetix, a bioscientific company centered around products to optimize molecular genomic
workflows.

• In the podcast, Dr. Sharma and Dr. Carpenter talk about the healthcare industry's need to optimize workflow and reduce costs in laboratory testing.
• Their company, Scienetix, is working on developing extraction-free tests that will eliminate the need for sample pre-processing and make testing more accessible and cheaper for labs.
• They are also focused on increasing the multiplex capability of PCR reactions, which will allow labs to test for more targets in a single reaction.
• Dr. Sharma and Dr. Carpenter also discuss their leadership styles and offer advice on being reliable, thinking about the application of science, and staying creative.
• They express concern about the growing distrust of science and the spread of misinformation, particularly in the age of social media.
• What excites them most is the opportunity to solve scientific challenges and create products that have a societal impact.

01:29 Tell to listeners about yourself

05:02 Talking about more sort of translation from selling to, going to start up

06:26 What led you to focus more on reagents and chemicals in scientist.com

08:05 Talking about more on Scientist.com

12:26 What are some key problems customers want to deal with, when they come to Scientist.com

14:14 Example of initiatives that they might look into use of your system

16:05 Are you working also with the suppliers or some of the clients

17:56 How does Scientist.com start to work with the customer

19:08 If have any idea how to start up your system

19:57 There are three questions that I like to ask every guest.

          -What Inspires you?

21:07 -What concerns you? 

22:37 -What excites you?

In this episode, I interview Francesco Salituro Independent Consultant at Salituro MedChem Solutions. Francesco has a tremendous background in drug development and he is helping a lot of early-stage companies. Additionally, Frank has supported the Epilepsy Foundation of New England for years because of his son Joseph. Joseph passed away from SUDEP (Sudden Unexplained Death in Epilepsy) which initiated the creation of Joseph's HOPE (Helping Other People with Epilepsy) Scholarship Fund. We discuss Francesco's career, drug discovery and his active life in the Epilepsy Foundation of New England after the loss of his son, in this episode.

Today on the Life Science Success podcast my guest is Oksana Bovt.  Oksana is the founder of Theoria Creative, an agency that develops unique fundraising materials enabling biotech and life sciences clients to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers.

• Oksana Bovt helps biotech companies communicate their scientific innovations to investors and potential partners.
• She emphasizes the importance of crafting an interesting story to grab investors' attention.
• Her company, Theoria Creative, is known for translating complex science and creating visual and illustrative materials, such as investor decks, scientific illustrations, and scientific animations.
• Theoria Creative works mostly on referral and helps companies that are ready to communicate effectively and have a clear direction.
• Oksana Bovt's background in science and advertising helps her to understand and communicate complex scientific concepts effectively.
• Theoria Creative helped a company with a broad oncology pipeline clarify their story and focus on approaching oncology and cancer holistically, resulting in a successful oversubscribed round and public offering.
• Oksana Bovt's best career advice is to understand oneself first and pursue what one is good at and passionate about.
• She is inspired by her clients and concerned about the global economy and the safety of her team in Ukraine.
• Her dog excites her and reminds her to take breaks and enjoy the outdoors.

This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences.

• Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal.

• Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies.

• ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector.

• Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework.

• Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.

Today on the Life Science Success Podcast, we have a very special guest with us—David Hibbard, the Vice President of Engineering at Sunrise Labs. With over 25 years of experience in medical device development, David has been at the forefront of innovation in areas ranging from Stress Echocardiography to Robotics.

• The interview features David Hibbard, VP of Engineering at Sunrise Labs, who has over 25 years of experience in medical device development. He holds a biomedical engineering degree from Boston University.

• Sunrise Labs specializes in Class II and Class III medical devices and focuses on end-to-end service, from software to hardware. The team size is just under 100 people, with approximately 70 to 80 engineers.

• David discusses the importance of strong project management, emphasizing the need to understand regulatory strategy and timelines, and advises that good client relationships are formed through transparency and integration, even in daily scrums.

• On the topic of leadership, David mentions the importance of good integrity and communication for long-term partnerships. He emphasizes that understanding the end user's needs is crucial for successful medical device development.

• Hibbard also talks about the use of AI to improve code robustness and mentions some of the challenges they are facing with remote work and maintaining a work-life balance in the current environment.

In this episode, I interview Debora Barton, MD, and we discuss Carisma Therapeutics (CAR-T, CAR-M, Macrophage, and Cancer Therapies) as well as her new board role at Tigerlily Foundation.

In this episode of the Life Science Success Podcast, my guest is Artem Britchenko.  Artem is the CEO of Platforce, which helps companies that interact with healthcare professionals and care about the efficiency and compliance of these interactions. He has been working in the B2C Pharma industry, helping companies improve their sales force effectiveness, customer engagement, and customer centricity.

• Don Davis, PhD, MBA interviews Artem Brytchenko, CEO of Platforce
• Platforce is a CRM solution tailored to the unique needs of the life sciences industry
• The solution includes closed loop marketing, remote capabilities, consent collection, distributor order optimization, and more
• The biggest challenges faced by Platforce include constant innovation and adaptation, scaling operations, and managing a global, distributed team
• The biggest opportunities include the rapid digital transformation of the life sciences industry, expanding to new geographies and markets, and serving adjacent sectors within healthcare
• Artem is inspired by his team, challenges, and family, concerned about the rapidly changing technological landscape and global complexities, and excited about fostering innovation and collaboration, technological advancements, and personal growth and happiness

In this episode of the Life Science Success Podcast, we're honored to have Dr. Alan Trounson, the CEO of Cartherics Pty Ltd, a company at the forefront of redefining cancer treatment through immunotherapy. Tune in as we discuss the future of cancer treatment, and much more!"

• Dr. Alan Trounson, CEO of Cartherics Pty Ltd, has a rich background in reproductive sciences and stem cell research. He has been instrumental in the development of human IVF and embryonic stem cells, and has also led the California Institute for Regenerative Medicine with a $3 billion budget.

• Cartherics aims to redefine cancer treatment through immunotherapy. The company is working on off-the-shelf CAR-T therapies that are designed to be low-cost and widely accessible, aiming to make cancer a manageable condition rather than a terminal one.

• The company differentiates itself by focusing on overcoming immune inhibitors in solid tumors and recruiting the patient's own immune system for a more effective treatment. They are also involved in gene editing to extend the life of CAR-T cells and make them more effective.

• Cartherics is in discussions with the FDA and plans to enter clinical trials by 2025. They are also collaborating with various international partners, including companies in Korea, China, Malaysia, and Australia, to bring in innovative ideas and technologies.

• Dr. Trounson is enthusiastic about the science and the potential impact of their work. He believes that getting the science right is crucial for achieving the expected outcomes and is excited about the broader scientific developments in the field.

In this episode of Life Science Success my guest is Dr Dr. Rahul Kakkar we will dive into the life and innovations of his tremendous career. From founding groundbreaking biotech companies to his vital role at Tome Biosciences and balancing life as a practicing physician, Rahul's journey is nothing short of inspirational. Discover the cutting-edge of genomic medicine and get a peek into the mind of a true life sciences pioneer.

• Dr. Rahul Kakkar's Journey: Dr. Kakkar, CEO of Tome Biosciences and a distinguished biotech executive and physician scientist, shares his journey from training in the Harvard Hospital System to his disillusionment with academia's limitations on drug development. This frustration led him towards a career in biotech, underscored by his entrepreneurial spirit and the significant influence of mentors who supported him at pivotal moments.

• Entrepreneurial Shift and Tome Biosciences: His experiences, particularly at AstraZeneca, highlighted the challenges of navigating entrenched corporate cultures, sparking his entrepreneurial journey. This journey includes the founding of Corvidia Therapeutics and ultimately leading to his current role at Tome Biosciences, where he emphasizes a flat, open company culture focused on innovative drug development.

• Balancing Medicine and Leadership: Kakkar balances his roles as a physician and a biotech leader, finding real-world clinical experiences vital for grounding his work in biotech. He maintains an active part in patient care, which he finds complements his leadership in biotech, keeping his work relevant and impactful.

• Advancements in Biotech and Tome's Focus: Kakkar discusses the evolution of biotechnology, from monoclonal antibodies and nucleotide-based therapeutics to the future of DNA editing. At Tome Biosciences, the focus is on programmable genomic integration, aiming to create differentiated, impactful drugs. This approach underscores the importance of technology in developing meaningful new therapies.

• Leadership Philosophy and Inspiration: Sharing insights on leadership, Dr. Kakkar emphasizes the importance of resilience, adaptability, and making the best of situations. He finds inspiration in the human spirit's perseverance, whether in family, healthcare, or scientific discovery, driving him to overcome challenges in healthcare and biotech innovation.

In this episode of Life Science Success, my guest is Michelle Briscoe, the Chief Operating Officer and Chief Financial Officer of Talus Bio. We dive into Michelle's extensive 26-year career in leading scientific organizations and her current role at Talus Bio. Michelle shares insights on the company's innovative MARMOT platform for drug discovery, targeting "undruggable" transcription factors. We explore her strategies for creating exceptional workplaces, her experience with M&A, and her co-founding of OUTbio Seattle. Michelle also discusses balancing financial and operational demands in biotech, industry trends, and her leadership philosophy.

In this episode of Life Science Success my guest is Kristofer Mussar.   Kristofer graduated from University of Georgia with a PhD in Molecular Genetics where he focused on Epigenetics and Evolution. He simultaneously obtained his MBA from the Terry College of Business.  He is currently the Managing Director and COO of VectorBuilder Inc.

• Kristofer Mussar, PhD, discusses his company Vector Builder and their innovative gene delivery methods.
• Vector Builder's platform is free to use and includes a design team for gene delivery methods.
• They are working on several R&D projects, including a capsid evolution for novel capsids, a bacterial backbone-free plasmid, and antibody-conjugated lipo nanoparticles with mRNA.
• Vector Builder emphasizes collaboration and treating researchers as collaborators.
• Mussar believes in the importance of genetics and personalized medicine.
• Vector Builder has a new software-based platform called Vector B in development.

In this episode of the Life Science Success Podcast, I am interviewing Dr. Stavros Papadopoulos, the founder and CEO of TileDB, Inc. We delve into Dr. Papadopoulos's journey from academia to entrepreneurship, exploring how his experiences at Intel, MIT CSAIL, and in Hong Kong shaped his innovative approach to data management. Dr. Papadopoulos shares insights on TileDB's mission to revolutionize data analytics in life sciences, discussing the unique features of their data management system and how it's addressing critical challenges in genomics and other scientific fields. We also explore the future of big data in life sciences, leadership in tech startups, and Dr. Papadopoulos's personal inspirations and concerns about the industry.

00:00 Introduction to Life Science Success Podcast
00:43 Sponsor Message from D3 Digital Media Marketing
01:19 Interview with Dr. Stavros Papadopoulos Begins
01:51 Dr. Papadopoulos' Background and Journey
02:33 The Birth of TileDB
03:16 Technical Innovations of TileDB
05:27 TileDB's Impact on Life Sciences
09:07 Influence of MIT and Intel on TileDB
10:40 Entrepreneurial Journey and Challenges
14:36 TileDB's Mission and Vision
15:58 Real-World Applications and Collaborations
25:45 Leadership and Business Insights
34:44 Final Thoughts and Reflections
41:37 Conclusion and Podcast Wrap-Up

Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.

He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.

In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.

This week on the Life Science Success Podcast, my guest is Stefan Lukianov.  Stefan is the Founder/CEO of Salve Therapeutics, a biotech company in LA building viral biologics with computational tools. 

In this episode, I interview Ken Banta Founder and Principal of the Vanguard Group. Ken has distinctly worked in the Life Sciences Industry with Pharmacia & Upjohn and Schering-Plough. He continues to work with CEO's and teams growing capabilities and changing the landscape for leadership in healthcare and life sciences. We dive into the shifts he has seen over the past year in delivery methods for his content as well as some key topics from his Harvard Business Review articles.

Today on the Life Science Success my guest is Yash Sabharwal. Yash is the CEO of CherryCircle Software. He is passionate about bringing novel software solutions to the life science industry to accelerate novel therapies to patients with lower development costs. At CherryCircle Software, the team has defined a new category of software for product quality and lifecycle management to facilitate digital maturity in pharma/biotech manufacturing.

In this episode of the Life Science Success Podcast my guest is Ann Conn, a triple board-certified physician and Chief Medical Officer of NeuroGlympse a pioneering TBI diagnostics company. With her deep clinical expertise in Pain Management, Neurology, and Headache Medicine, Ann brings a passion for innovation and strategic thinking to improve patient care.

00:00 Introduction to the Podcast
00:40 Meet Dr. Anne Conn
01:01 Dr. Conn's Journey in Medicine
02:42 Innovative Pain Management Techniques
03:43 Don's Personal Health Story
05:03 Understanding Patient Symptoms
12:19 NeuroGlympse and Concussion Diagnosis
19:02 Challenges and Innovations
23:05 Understanding Heart Rate Variability
24:16 The Brain-Heart Connection
26:44 Remote Therapeutic Monitoring Explained
29:59 Success Stories and Patient Impact
31:50 Vagus Nerve Stimulation for Migraines
34:02 Innovations in Migraine Treatment
36:54 Inspiration and Concerns in Medicine
39:13 Exciting Future of Brain Health
41:54 Conclusion and Final Thoughts

In this episode of Life Sciences Success, my guest is Sharon Rogers the CEO of AmyriAD.  Sharon brings the strength of her 35 years of pharmaceutical experience to AmyriAD. She is best known as the worldwide leader and development strategist for the highly successful AD treatment, Aricept. Aricept has been the standard of care for more than 20 years, and no other AD program has produced more compelling results.

• Sharon L. Rogers, a research scientist, talks about a new drug for Alzheimer's disease
• The drug, AD101, is designed to improve cognition and global function in Alzheimer's patients
• It is a cholinergic drug, but its action is limited to the brain, making it more effective than other cholinergic drugs
• The drug has gone through phase two trials and is now moving into phase three
• Rogers also discusses her experience as an expat in Japan and the importance of resilience and leadership
• She expresses concern about complacency and outrage fatigue
• Rogers is excited about the potential of Gen Z to effect change

In this episode of Life Science Success, I interviewed Dirk Abeel.  He is a consultant in Life Sciences who focuses on implementing a new commercial model called Omnichannel.  If your commercialization efforts need a shift in focus this episode is for you.    

Notes:

1:02 Dirk's career in marketing, sales and sales enablement. 

5:57 Dirk's work in Africa

7:17 What is Omnichannel

9:55 How Omnichannel is deployed

12:00 The power of data 

15:25 The importance of mindset

19:37 The transition to the future may not be fully face-to-face selling

23:50 Engraining the behavior in the sales team

33:00 The importance of having the right data

36:24 Three questions:

• What excites you
• What concerns you 
• What inspires you

To connect with the guest, links and show notes please visit: www.lifesciencesuccess.com

In this episode we switch gears and talk about two topics that have not yet been covered on the podcast, bioprocess and construction.  Erich has an interesting background and is helping bioprocessing facilities grow to meet the demands of both new drugs that are being developed and at the moment facilities that are preparing for both COVID-19 drugs and possibly vaccines.

In this episode of the Life Science Success Podcast I interview Reed Mclaughlin and Kelly Malloy from Anju Software. Our discussion centers around Reed and Kelly’s perspectives on the evolution of the Medical Affairs function, how it continues to emerge as a strategic pillar within life sciences organizations, and its critical importance to driving patient outcomes. They will further discuss how Anju Software medical affairs solutions like IRMSmax and PUBSTRATmax are being leveraged to optimize work across medical affairs to increase effectiveness and leverage insights to ensure the right information is delivered to the right person at the right time.

This week on the Life Science Success Podcast my guest is Nathan Clark.  Nathan is the co-founder of Ganymede and is passionate about biotechnology. He is at the frontier of biology and engineering, and has merged his profound knowledge in this field with business development to reimagine data infrastructure in the life sciences.

• Nathan Clark discusses his company's goal to become the infrastructure for the life sciences industry
• The industry is moving slowly in terms of digital transformation and data integration
• The complexity of data in the life sciences industry is a unique problem that requires a science of managing that complexity
• Instrument manufacturers are inhibiting connectivity by putting all their data into different formats
• The goal is to create a centralized data lake that can be mapped together and linked
• The complexity of the industry and the slow pace of digital transformation concerns Nathan Clark
• Nathan Clark is excited about the potential for scientific advancements in the life sciences industry, including understanding epigenetics and how biological systems interact with each other

In this episode of Life Science success I interviewed April Zambelli-Weiner PhD.  April is the CEO of TTi Health Research & Economics.  At TTi they provide life cycle clinical and economic research and consulting services to guide strategic decisions from pre-market development through commercialization and growth, enabling companies to demonstrate and evolve their product’s true differentiated value story.

Joe is the CEO of STAQ Pharma and has previously been the leader, CEO and entrepreneur for three other startups in Life Sciences:

• Sharklet
• RevGen
• BIOamps

For more detailed information about the show, show notes and links to Joe please visit www.lifesciencesuccess.com

In this episode of Life Science Success my guest is Jason Mundin, MBA who is the CEO of Ubiquigent.  Jason has over 30 years’ experience in the pharmaceutical and biotechnology industries. He joined Ubiquigent in 2015 as Commercial Director, becoming Managing Director in 2018 and CEO in 2021. 

• Jason Mundin is the CEO of Ubiquigent, a biotech company that focuses on drug discovery
• They have taken the company from a loss-making biotech to a profitable one.
• They are now focused on becoming a drug discovery-focused therapeutics company.
• They are actively engaged in securing inward investment.
• They are concerned about the state of funding for the life sciences industry.
• They are excited about the potential of their programs and the value they can bring to the industry.
• They believe that innovation is necessary due to limited resources and are constantly looking for ways to be innovative.
• They are excited to attend conferences and connect with people who are interested in their work.

In this episode of the Life Science Success Podcast my guest is Chris Anderson.  Chris is a seasoned Pharmaceutical Professional with more than 20 years of experience in multiple fields within the Industry.

• Don Davis and Chris Anderson discuss the regenerative medicine industry
• Chris highlights the need for partnerships between companies and government entities
• The challenges of ensuring compliance and patient safety in a new and evolving industry are discussed
• Chris talks about being inspired by the people and ideas in the industry
• They both express excitement about the potential for future advancements in regenerative medicine and other areas like AI.

This week on the Life Science Success podcast I interview Josh Seidenfeld. Josh is a partner with Cooley LLP in the Palo Alto office. His practice consists of representing clients on general corporate matters, with a focus on emerging companies, private financing, initial public offerings, and mergers & acquisitions. Prior to joining Cooley, he was the Director of Business Development and Corporate Counsel for Practice Fusion, an electronic health record company located in the San Francisco Bay Area.

In this episode of the Life Science Success Podcast I am back with Gary McAuslan the CEO of aCGT Vector and we are discussing the growth of the company. 

This week on the Life Science Podcast I am interviewing Fungai Ndemera.  Fungai is the CEO of Checkup Health.  Fungai and I are going to talk about her journey to becoming the CEO, Diversity and we are going to cover her focus as a Keynote speaker.  

00:58  Introduction for Fungai and greeting

01:18  Telling to listeners a bit about yourself

02:07  Lead you to Create Check Up Health company

04:52  More about Check Up Health company function and how it helps

08:04  How it works with populations get involved and limiting biases

10:26  How targeted populations shift and leverage technology, considering diversity

12:37  About being panelist and discussion with the Melan and medic panel

15:55  One of the Social Media posts thought provoking question

• What are the best ways that a business could reduce health inequalities?

20:23 What oftentimes do you speak about as a Keynote speaker, whenever on stage?

22:02 Three Question

 -What Inspires you?

 -What concerns you? 

 -What excites you?

In this episode of Life Science Success, we sit down with Katrina Rogers, a change expert with over 25 years in life sciences, dedicated to transforming the way therapies are brought to market. Katrina, an ASQ-certified Manager of Quality/Organizational Excellence and Pharmaceutical GMP Professional, shares insights on her mission to reduce costs and accelerate timelines in drug development.

She walks us through her journey, her company’s impactful work, and the innovative strategies she employs to streamline operations in life sciences. Join us as Katrina reveals the leadership lessons that inspire her and the exciting future of pharmaceutical advancements.

In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin.  We are going to discuss derisking the supply chain and building resilience.

Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.

Michael Patterson is a Health Care Executive with over 27 years of experience in the following areas (Cannabis/CBD/Hemp Investing, Operations, Laws, Regulation, Compliance, Banking, Digital Assets/ Cryptocurrency, Management, and International trade, Skilled Nursing, Assisted Living, Home Healthcare, Therapy Management, Laboratory, Pharmacy Management, and Health Care Analytics).

This week on Life Science Success Podcast my guest is Yan Leyfman, MD is a unique individual in life sciences and is someone we all need to be paying attention to. Yan was raised in the medically deprived community that was ravaged by the Chernobyl nuclear disaster. Today, we are going to talk about his experience with Chernobyl, how that led to his career in medicine and what he has done to turn struggles into triumphs.

This is my first time having a returning guest on the Life Science Success Podcast. Trivia Frazier, PhD, MBA sat down with me to give me an update on Obatala Sciences. They are currently expanding their commercial team and overall footprint. It was such a blast to sit down with someone who has been on the show previously.

In this episode of the Life Science Success Podcast from Bio in the Bayou 2022, I sit down with Paul Romness the founder of OS Therapies. During our interview Paul shares his absolute passion for Osteosarcoma. He shares that roughly 1000 children will get osteosarcoma each year and roughly 50% will die. (Paul agreed to let me share the emotion expressed during the interview)

I greatly appreciate companies that are attacking problems like this and look forward to seeing OS Therapies in the news as they go public.

For more information, links and show notes please visit:www.lifesciencesuccess.com

Dr. Mark Collins talks about how Helomics uses AI (Artificial Intelligence) to find patterns in Ovarian Cancer treatments that have been applied to 35,000 patient’s responses to certain drugs.  This data has been used on both the drug discovery and clinical side of developing a functional tumor profile and possible mutation information for ovarian cancer patients.  

Lee is a results-focused operations executive in biotech and medical devices with deep experience in leveraging lean six sigma methodologies to drive cost-saving initiatives and improve operational efficiency in an organization. He has a great ability to motivate, encourage, and develop high-performing teams helping individuals take their performance to the next level.

In this episode of Life Science Success, my guest is Brian DeDecker.  Brian is the CEO and co-founder of Seedling Biosystems in Boulder, Colorado. The planet’s ecosystems strain from current chemical and protein manufacturing methods and Brian co-founded Seedling to help solve this crisis. 

🔑 Key Takeaways:

1️⃣ Empathy in Communication: Whether talking to students or venture capitalists, understanding your audience's mindset is crucial. Brian shares how teaching has honed his skills in this area.

2️⃣ Sustainable Biomanufacturing: Seedling Biosystems aims to revolutionize industries by shifting processes to farming, particularly focusing on soybeans as a sustainable alternative.

3️⃣ Innovative Products: From baby formula proteins to squalene for vaccines, Seedling is working on products that not only meet market needs but do so in an eco-friendly manner.

4️⃣ Leadership Philosophy: "Do what you can with what you got, where you are." This Teddy Roosevelt quote serves as Brian's guiding principle, emphasizing resourcefulness.

5️⃣ Climate Change: Both a concern and a motivator, Brian believes that the challenges posed by climate change will bring out the best in humanity, driving us toward innovative solutions.

Rebecca D. Costa is an American sociobiologist and futurist. She is the preeminent global expert on the subject of "fast adaptation" and recipient of the prestigious Edward O. Wilson Biodiversity Technology Award. Her career spans four decades of working with founders, executives and leading venture capitalists in Silicon Valley. Costa's work has been featured in the New York Times, Washington Post, USA Today, The Guardian, and other leading publications.

We have a fantastic conversation about her books "The Watchman's Rattle" and "On the Verge"

At the end of the podcast, Rebecca shares with me her thoughts on new technologies that will be coming in the future.